- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Health experts hail Centre move to exempt 3 more cancer drugs from Customs duty
![Health experts hail Centre move to exempt 3 more cancer drugs from Customs duty Health experts hail Centre move to exempt 3 more cancer drugs from Customs duty](https://medicaldialogues.in/h-upload/2024/06/07/750x450_240455-medicine.webp)
New Delhi: Health experts expressed appreciation on Tuesday for the central government's decision to exempt three additional cancer drugs from Customs duty. However, they rued that longstanding demands, such as increasing the GDP spend on healthcare to 2.5 per cent, were not addressed in the Union Budget. The exempted drugs include Trastuzumab deruxtecan, used for treating breast cancer or gastroesophageal adenocarcinoma, Osimertinib, beneficial for lung cancers with specific mutations, and Durvalumab, prescribed for lung and biliary tract cancers.
By exempting these drugs from Customs duty, the government has taken a concrete step towards alleviating the significant financial burden cancer treatment often involves, Dr Ashutosh Raghuvanshi, MD and CEO of Fortis Healthcare Limited said.
Read also: Indian pharma, healthcare sector record 55 deals totaling USD 4.1 billion in Q2 2024
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751